CClinicalTrials.gg
Sign In
Status unknownNCT05291663Updated Mar 23, 2022

Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck

An observational study in Head and Neck Squamous Cell Carcinoma, sponsored by Assiut University. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Evaluation of the efficacy of the accelerated radiotherapy in squamous cell carcinoma of head and neck

Read the detailed description
  • HNSCC is the sixth most common cancer worldwide, with 890.000 new cases and 450.000 deaths in 2018.
  • The incidence of HNSCC continues to rise and is anticipated to increase by 30% (that is, 1.08 million new cases annually) by 2030.
  • Squamous cell carcinoma constitutes 90% of all head and neck cancers and it predominates in males.
  • Risk factors such as cigarette consumption and alcohol consumption, are well established.
  • Treatment decisions are guided by clinic-pathologic factors such as age and stage.
  • Treatment of the majority of patients with HNSCC requires multimodality approaches.
  • Radiotherapy or surgery alone can be considered as the standard treatment modality for patients having early head and neck squamous cell carcinoma.
  • When conventionally fractionated radiotherapy is used, long-term tumor control can be achieved in less than 30% of patients with advanced head and neck carcinomas.
02

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 100 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

-Patients of (18 up to 75 years of age)

Inclusion criteria

  • Patients of (18 up to 75 years of age)
  • Performance status of 0-2 according to ECOG scale.
  • Patients with no prior chemotherapy, radiotherapy or surgery except for biopsy.

Exclusion criteria

Exclusion Criteria:

  • Patients with previous irradiation to head and neck.
  • Pregnant or lactating women.
  • Patients with impaired heart or lung diseases.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Determine progression-free survival rate

    Determine the toxicity and loco-regional control by using accelerated RTH in squamous cell carcinoma in head and neck

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6. PubMed 30350310 ↗
  • Windon MJ, D'Souza G, Rettig EM, Westra WH, van Zante A, Wang SJ, Ryan WR, Mydlarz WK, Ha PK, Miles BA, Koch W, Gourin C, Eisele DW, Fakhry C. Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer. 2018 Jul 15;124(14):2993-2999. doi: 10.1002/cncr.31385. Epub 2018 Apr 30. PubMed 29710393 ↗
  • Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988 Jun 1;48(11):3282-7. PubMed 3365707 ↗
  • Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3. Erratum In: Nat Rev Dis Primers. 2023 Jan 19;9(1):4. doi: 10.1038/s41572-023-00418-5. PubMed 33243986 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05291663
Lead sponsor
Assiut University
Responsible party
Zienab Kamel Mahmoud (Doctor, Assiut University) — Principal investigator
First posted
Mar 23, 2022
Start date
Mar 20, 2022 (estimated)
Primary completion
Mar 20, 2023 (estimated)
Completion
Dec 20, 2023 (estimated)
Last update
Mar 23, 2022

Study contacts

Zienab Kamel
Contact
zienab95kamel@gmail.com
+201022997677
Mostafa El-sayed Abd Elwanis
Contact
Mostafa.wanis@aun.edu.eg
+201221133032
Mostafa El-sayed Abd Elwanis
study director · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

Assiut University

Start the discussion